Biological therapy of severe bronchial asthma in children: Indications and effectiveness criteria

Bronchial asthma is one of the most common chronic diseases in children. Severe asthma is defined by the European Respiratory Society and American Thoracic Society as asthma that requires treatment with high-dose combination therapy of inhaled corticosteroids in combination with long-acting bronchodilators and/or with the use of systemic corticosteroids, or remains uncontrolled despite treatment. In the structure of severity, severe asthma occupies about 5%, but it leads to a maximum decrease in quality of life, causes disability, and also requires significant expenditure of health care resources. Therefore, selection of therapy for severe bronchial asthma remains an important task. The introduction of monoclonal antibody drugs into practice makes it possible to improve the control of severe bronchial asthma in children at the 5th stage of therapy. The first biological drug to treat severe asthma was Omalizumab, and over twenty years of its use has been shown to be effective in controlling symptoms, reducing the frequency of exacerbations, and improving lung function. Our study assessed the effectiveness of biological therapy. Treatment with omalizumab led to in a reduction in the frequency of symptoms, number of exacerbations, total IgE, and improvement of lung function as assessed by spirography. No severe reactions to the drug were observed. The article presents a clinical example of long-term use of omalizumab in a patient with severe bronchial asthma, which made it possible to achieve control over the disease, improve quality of life and reduce the volume of basic therapy, while no adverse reactions to the drug were recorded.

1. Szefler SJ, Fitzgerald DA, Adachi Y, Doull IJ, Fischer GB, Fletcher M et al. A worldwide charter for all children with asthma. Pediatr Pulmonol. 2020;55(5):1282–1292. https://doi.org/10.1002/ppul.24713.

2. Haktanir Abul M, Phipatanakul W. Severe asthma in children: Evaluation and management. Allergol Int. 2019;68(2):150–157. https://doi.org/10.1016/j.alit.2018.11.007.

3. Asher MI, Rutter CE, Bissell K, Chiang CY, El Sony A, Ellwood E et al. Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study. Lancet. 2021;398(10311):1569–1580. https://doi.org/10.1016/S0140-6736(21)01450-1.

4. Tsuge M, Ikeda M, Tsukahara H. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. Children. 2022;9(8):1253. https://doi.org/10.3390/children9081253.

5. Glasser SW, Hardie WD, Hagood JS. Pathogenesis of Interstitial Lung Disease in Children and Adults. Pediatr Allergy Immunol Pulmonol. 2010;23(1):9–14. https://doi.org/10.1089/ped.2010.0004.

6. Ubags NDJ, Alejandre Alcazar MA, Kallapur SG, Knapp S, Lanone S, Lloyd CM et al. Early origins of lung disease: towards an interdisciplinary approach. Eur Respir Rev. 2020;29(157):200191. https://doi.org/10.1183/16000617.0191-2020.

7. Pamuk G, Le Bourgeois M, Abou Taam R, de Blic J, Delacourt C, Lezmi G. The economic burden of severe asthma in children: a comprehensive study. J Asthma. 2021;58(11):1467–1477. https://doi.org/10.1080/02770903.2020.1802747.

8. Pijnenburg MW, Fleming L. Advances in understanding and reducing the burden of severe asthma in children. Lancet Respir Med. 2020;8(10):1032–1044. https://doi.org/10.1016/S2213-2600(20)30399-4.

9. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. https://doi.org/10.1183/09031936.00202013.

10. Howell I, Howell A, Pavord ID. Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight. J Exp Med. 2023;220(7):e20221212. https://doi.org/10.1084/jem.20221212.

11. Santos-Valente E, Buntrock-Döpke H, Abou Taam R, Arasi S, Bakirtas A, Lozano Blasco J et al. Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo. ERJ Open Res. 2021;7(3):00143-2021. https://doi.org/10.1183/23120541.00143-2021.

12. Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular Targets for Biological Therapies of Severe Asthma. Front Immunol. 2020;11:603312. https://doi.org/10.3389/fimmu.2020.603312.

13. Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I et al. Efficacy and safety of treatment with biologicals (benralizumab. dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1043–1057. https://doi.org/10.1111/all.14235.

14. Tenero L, Rossignoli S, Piacentini G. Severe asthma: When to resort to biological agents. Pediatr Allergy Immunol. 2020;31(Suppl. 24):37–39. https://doi.org/10.1111/pai.13162.

15. Marseglia GL, Licari A, Tosca MA, Ciprandi G. Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update. Pediatr Allergy Immunol Pulmonol. 2020;33(4):168–176. https://doi.org/10.1089/ped.2020.1212.

16. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. https://doi.org/10.1016/j.jaci.2015.09.008.

17. Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumab: what we still have to learn. Biologics. 2018;12:135–142. https://doi.org/10.2147/BTT.S180846.

18. Domingo C, Mirapeix RM, González-Barcala FJ, Forné C, García F. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study. Drugs. 2023;83(12):1111–1123. https://doi.org/10.1007/s40265-023-01905-5.

19. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015. https://doi.org/10.1056/NEJMoa1009705.

20. Henriksen DP, Bodtger U, Sidenius K, Maltbaek N, Pedersen L, Madsen H et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol. 2020;16:49. https://doi.org/10.1186/s13223-020-00442-0.

21. Busse WW, Humbert M, Haselkorn T, Ortiz B, Trzaskoma BL, Stephenson P et al. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2020;124(2):190–196. https://doi.org/10.1016/j.anai.2019.11.016.

22. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83(6):520–528. https://doi.org/10.1159/000334701.

23. Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–609. https://doi.org/10.1136/archdischild-2011-301570.

24. Fayzullina RM, Sannikova AV, Shangareeva ZA, Absalyamova NT, Valeeva ZhA. Targeted therapy of bronchial asthma in children. Medical Herald of the South of Russia. 2022;13(2):134–140. (In Russ.) https://doi.org/10.21886/2219-8075-2022-13-2-134-140.

25. Zaytseva SV, Tomilova AU, Zaytseva OV, Voronina OB, Murtazaeva OA, Mukhortykh VA, Tsymbal IN. Genetically Engineered Biologic Drugs in Management of Children with Bronchial Asthma. Pediatric Pharmacology. 2021;18(6):460–468. (In Russ.) https://doi.org/10.15690/pf.v18i6.2325.

26. Zastrzeżyńska W, Przybyszowski M, Bazan-Socha S, Gawlewicz-Mroczka A, Sadowski P, Okoń K et al. Omalizumab may decrease the thickness of the reticular basement membrane and fibronectin deposit in the bronchial mucosa of severe allergic asthmatics. J Asthma. 2020;57(5):468–477. https://doi.org/10.1080/02770903.2019.1585872.

27. Deschildre A, Marguet C, Salleron J, Pin I, Rittié JL, Derelle J et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224–1233. https://doi.org/10.1183/09031936.00149812.

28. Shnaider KO, Maksimov ML, Romanov BK. Safety of omalizumab in the treatment of moderate-to-severe bronchial asthma. Medical Journal of the Russian Federation. 2022;28(1):89–98. (In Russ.) https://doi.org/10.17816/medjrf108909.

29. Khaleva E, Rattu A, Brightling C, Bush A, Bossios A, Bourdin A et al. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA). Eur Respir J. 2023;61(4):2200606. https://doi.org/10.1183/13993003.00606-2022.

30. Licari A, Manti S, Chiappini E, Ciprandi G, Marseglia GL. Severe asthma in children: Current goals and unmet needs. Pediatr Allergy Immunol. 2020;31(Suppl. 24):40–42. https://doi.org/10.1111/pai.13168.